Morgan Stanley
LUMO

Morgan Stanley’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Morgan Stanley’s Portfolio LUMO Stock Details LUMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-166
Closed -$642 – 8165
2024
Q3 		$642 Sell
166
-111
-40% -$307 ﹤0.01% 7275
2024
Q2 		$643 Buy
277
+111
+67% +$287 ﹤0.01% 7201
2024
Q1 		$468 Sell
166
-166
-50% -$492 ﹤0.01% 7244
2023
Q4 		$1.06K Buy
332
+210
+172% +$715 ﹤0.01% 7200
2023
Q3 		$403 Sell
122
-222
-65% -$692 ﹤0.01% 7331
2023
Q2 		$1.14K Hold
344
– – ﹤0.01% 7278
2023
Q1 		$1.14K Hold
344
– – ﹤0.01% 7333
2022
Q4 		$1.24K Hold
344
– – ﹤0.01% 7440
2022
Q3 		$3K Hold
344
– – ﹤0.01% 7408
2022
Q2 		$3K Sell
344
-918
-73% -$7.34K ﹤0.01% 7535
2022
Q1 		$12K Buy
1,262
+35
+3% +$313 ﹤0.01% 7357
2021
Q4 		$8K Buy
1,227
+94
+8% +$790 ﹤0.01% 7545
2021
Q3 		$10K Hold
1,133
– – ﹤0.01% 7336
2021
Q2 		$12K Sell
1,133
-359
-24% -$4K ﹤0.01% 7191
2021
Q1 		$17K Buy
1,492
+587
+65% +$9.87K ﹤0.01% 6785
2020
Q4 		$32K Sell
905
-36
-4% -$621 ﹤0.01% 6298
2020
Q3 		$13K Buy
941
+496
+111% +$7.41K ﹤0.01% 6192
2020
Q2 		$7K Sell
445
-213
-32% -$2.54K ﹤0.01% 6250
2020
Q1 		$6K Sell
658
-5,104
-89% -$71.3K ﹤0.01% 6163
2019
Q4 		$131K Buy
5,762
+4,341
+305% +$61.9K ﹤0.01% 5570
2019
Q3 		$21K Sell
1,421
-29
-2% -$425 ﹤0.01% 6000
2019
Q2 		$20K Sell
1,450
-6,469
-82% -$97.7K ﹤0.01% 5936
2019
Q1 		$138K Sell
7,919
-11,728
-60% -$175K ﹤0.01% 5242
2018
Q4 		$269K Buy
19,647
+3,619
+23% +$63.7K ﹤0.01% 5161
2018
Q3 		$345K Buy
16,028
+7,075
+79% +$215K ﹤0.01% 5199
2018
Q2 		$384K Sell
8,953
-3,081
-26% -$141K ﹤0.01% 5254
2018
Q1 		$785K Buy
12,034
+3,855
+47% +$273K ﹤0.01% 4722
2017
Q4 		$597K Buy
8,179
+3,344
+69% +$277K ﹤0.01% 4871
2017
Q3 		$443K Sell
4,835
-9,892
-67% -$759K ﹤0.01% 4955
2017
Q2 		$973K Buy
14,727
+5,134
+54% +$636K ﹤0.01% 4389
2017
Q1 		$2.08M Sell
9,593
-4,255
-31% -$608K ﹤0.01% 3769
2016
Q4 		$1.28M Buy
13,848
+11,565
+507% +$1.3M ﹤0.01% 4279
2016
Q3 		$309K Sell
2,283
-502
-18% -$49.9K ﹤0.01% 4793
2016
Q2 		$283K Sell
2,785
-5,551
-67% -$688K ﹤0.01% 4767
2016
Q1 		$1.37M Sell
8,336
-4,473
-35% -$907K ﹤0.01% 3665
2015
Q4 		$4.19M Sell
12,809
-7,534
-37% -$2.45M ﹤0.01% 2837
2015
Q3 		$6.56M Buy
20,343
+13,661
+204% +$6M ﹤0.01% 2396
2015
Q2 		$2.66M Sell
6,682
-7,676
-53% -$3.26M ﹤0.01% 3358
2015
Q1 		$7.07M Buy
14,358
+1,983
+16% +$768K ﹤0.01% 2416
2014
Q4 		$4.43M Buy
12,375
+1,869
+18% +$556K ﹤0.01% 2846
2014
Q3 		$2.02M Buy
10,506
+8,573
+444% +$1.88M ﹤0.01% 3421
2014
Q2 		$462K Sell
1,933
-4,909
-72% -$998K ﹤0.01% 4637
2014
Q1 		$1.75M Buy
6,842
+2,303
+51% +$704K ﹤0.01% 3535
2013
Q4 		$899K Sell
4,539
-870
-16% -$155K ﹤0.01% 4010
2013
Q3 		$915K Buy
5,409
+1,282
+31% +$206K ﹤0.01% 3873
2013
Q2 		$733K Buy
+4,127
New +$584K ﹤0.01% 3977

Morgan Stanley's LUMO Position: Q4 2024 in Review

Morgan Stanley sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q4 2024, closing a stake of 166 shares — an estimated $642 sold.

Morgan Stanley first reported a position in LUMO in Q2 2013 and held it in 46 quarters. The position peaked at $7.07M in Q1 2015. 0 funds tracked by Wall St. Rank hold LUMO as of Q4 2024.

  • Morgan Stanley reported no remaining Lumos Pharma, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • Morgan Stanley sold 166 Lumos Pharma, Inc. Common Stock shares in Q4 2024, an estimated $642.
  • Morgan Stanley first reported a position in Lumos Pharma, Inc. Common Stock in Q2 2013 and held it in 46 quarters.
  • Morgan Stanley's Lumos Pharma, Inc. Common Stock position peaked at $7.07M in Q1 2015.
  • 0 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q4 2024.

Based on Morgan Stanley's 13F filing for Q4 2024, filed 14 Feb 2025.